Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14

作者：

Chanthavanich, Pornthep ^{[1
]}

Limkittikul, Kriengsak ^{[1
]}

Sirivichayakul, Chukiat ^{[1
]}

Chokejindachai, Watcharee ^{[1
]}

Hattasingh, Weerawan ^{[1
]}

Pengsaa, Krisana ^{[1
]}

Surangsrirat, Surachai ^{[2
]}

Srisuwannaporn, Termsang ^{[2
]}

Kaewma, Benjawan ^{[2
]}

Yoksan, Sutee ^{[3
]}

Jun, Gao ^{[4
]}

Zhumu, Bai ^{[4
]}

机构：

[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand

[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand

[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand

[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期

关键词：

children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;

D O I：

10.1080/21645515.2017.1414763

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.

引用

页码：900 / 905

页数：6

共 50 条

[21] Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
Zhang, Yuntao
Chen, Haiping
Lv, Jun
Huang, Tao
Zhang, Ruizhi
Zhang, Dongjuan
Luo, Linyun
Wei, Sheng
Liu, Xiaoqin
Zhang, Shangxiao
Mu, Qiuyue
Huang, Rongdong
Huang, Jiao
Xiao, Yanhui
Yang, Yunkai
Han, Yuting
Gong, Hao
Guan, Qinghu
Xie, Fangqin
Wang, Hui
Li, Liming
Yang, Xiaoming
VACCINES, 2022, 10 (07)
[22] Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial
Yun, Ki Wook
Lee, Hoan Jong
Kang, Jin Han
Eun, Byung Wook
Kim, Yae-Jean
Kim, Kyung-Hyo
Kim, Nam Hee
Hong, Young Jin
Kim, Dong Ho
Kim, Hwang Min
Cha, Sung-Ho
BMC INFECTIOUS DISEASES, 2015, 15
[23] Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial
Ki Wook Yun
Hoan Jong Lee
Jin Han Kang
Byung Wook Eun
Yae-Jean Kim
Kyung-Hyo Kim
Nam Hee Kim
Young Jin Hong
Dong Ho Kim
Hwang Min Kim
Sung-Ho Cha
BMC Infectious Diseases, 15
[24] Booster effect of a new chromatographically purified Vero-cell rabies vaccine (CPRV):: immunogenicity and safety of a single or double injection
Picot, N
Le Mener, V
Rotivel, Y
Schönfeld, C
Cetre, JC
Costy, F
Grillet, JP
Lanta, N
Lang, J
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (03) : 342 - 344
[25] Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis
Tantawichien, Terapong
Sibunruang, Suda
Tantawichien, Thanphet
Angsanakul, Jaruboot
Benjavongkulchai, Maneerat
Limsuwan, Kornvika
Udomchaisakul, Piyada
Khomvilai, Sumana
Sitprija, Visith
EXPERT REVIEW OF VACCINES, 2014, 13 (12) : 1593 - 1601
[26] Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children
Angsuwatcharakon, Piyada
Khomvilai, Sumana
Limsuwun, Kornvika
Ratananpinit, Natchaya
Khamchat, Apinya
Sanitnai, Teeranit
Tantawichien, Terapong
EXPERT REVIEW OF VACCINES, 2018, 17 (02) : 185 - 188
[27] Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine
Arora, A
Moeller, L
Froeschle, A
JOURNAL OF TRAVEL MEDICINE, 2004, 11 (04) : 195 - 200
[28] The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis
Erra, Elina O.
Kantele, Anu
EXPERT REVIEW OF VACCINES, 2015, 14 (09) : 1167 - 1179
[29] Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
Qin, E
Shi, HY
Tang, L
Wang, C
Chang, GH
Ding, ZF
Zhao, K
Wang, J
Chen, Z
Yu, M
Si, BY
Liu, JY
Wu, DL
Cheng, XJ
Yang, BA
Peng, WM
Meng, QW
Liu, BH
Han, WG
Yin, XA
Duan, HY
Zhan, DW
Tian, L
Li, SL
Wu, JS
Tan, G
Li, Y
Li, YC
Liu, YG
Liu, H
Lv, FS
Zhang, Y
Kong, XG
Fan, BC
Jiang, T
Xu, SL
Wang, XM
Li, CW
Wu, XH
Deng, YQ
Zhao, M
Zhu, QY
VACCINE, 2006, 24 (07) : 1028 - 1034
[30] Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium
Toriniwa, Hiroko
Komiya, Tomoyoshi
VACCINE, 2008, 26 (29-30) : 3680 - 3689

← 1 2 3 4 5 →